Tyler Jacks - Amgen Insider

Amgen Inc -- USA Stock  

USD 170.12  0.16  0.0941%

Independent Director

Dr. Tyler Jacks Ph.D., is an Independent Director of Amgen Inc. Tyler Jacks joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, a position he has held since 2007. Dr. Jacks was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, since 1994. Dr. Jacks was a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since May 2009, and serves on its Strategy and Finance Committee and scientific advisory board. In 2006, he cofounded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks was a consultant scientific advisor to Epizyme, Inc., a biopharmaceutical company, since 2007, and has served on the scientific advisory board of SQZ Biotech, a privatelyheld biotechnology company, since 2015
Age: 55  Director Since 2012  Ph.D    
805 447-1010  www.amgen.com
Jacks served on the scientific advisory board of Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privatelyheld biopharmaceutical company, in 2015 and serves as coChair of its scientific advisory board. He was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, in October 2011. In April 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as coChair advising the Cancer MoonshotSM Task Force.

Management Efficiency

The company has return on total asset (ROA) of 8.27 % which means that it generated profit of $8.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 26.43 % meaning that it created $26.43 on every $100 dollars invested by stockholders.
The company currently holds 35.06 B in liabilities with Debt to Equity (D/E) ratio of 110.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 6.08 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Nancy HutsonEndo International plc
2009
Peter McDonnellAllergan plc
2015
Christopher CoughlinAllergan plc
2016
Adriane BrownAllergan plc
2017
Shane CookeEndo International plc
2014
Deborah NeffBio Rad Laboratories Inc
2011
Michael GallagherAllergan plc
2015
Bruce SachsVertex Pharmaceuticals Incorpor
2017
William YoungVertex Pharmaceuticals Incorpor
2014
James FarrellAbbott Laboratories
2006
Edward LiddyAbbott Laboratories
2010
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
Alice SchwartzBio Rad Laboratories Inc
1967
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Joseph BoccuziAllergan plc
2017
Louis DrapeauBio Rad Laboratories Inc
2007
David GreenwayVertex Pharmaceuticals Incorpor
2017
Todd SisitskyEndo International plc
2016
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Nesli BasgozAllergan plc
2014
Ronald TaylorAllergan plc
2013

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 17,900 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
R Williams, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators